Stem Cell Sciences goes US
Wednesday, 04 March, 2009
Technology company Stem Cell Sciences (SCS) is to be sold to Delaware’s StemCells Inc for close to US$5 million.
SCS, which has a research laboratory in Melbourne and is headquartered in Cambridge in the UK, has an impressive portfolio of IP based around technologies for stem cell research including cell-based assays, gene delivery vehicles, cell media and methodologies.
In a statement, the companies said it was expected that SCS’s 20 full-time staff will be retained if the deal goes ahead. Agreement has already been received from 30 per cent of SCS shareholders.
An EGM to vote on the deal will be held in London on 27 March.
Optimising antibiotics by capturing bacteria
Scientists have developed molecules to detect and capture certain bacterial species, in the hope...
HIV drugs suppress transmission of a different viral infection
The work could lead to the first treatments to prevent the spread of the life-threatening...
How cells repair toxic DNA damage
Researchers say they have uncovered the mechanism by which cells identify and repair a highly...
